Endocrine Abstracts

Neuroendocrine neoplasms (NENs) are a heterogeneous tumour classification including indolent neuroendocrine tumours (NETs), aggressive neuroendocrine carcinomas (NECs). NECs and small cell lung cancer (SCLCs) are poorly differentiated tumours and life expectancy following metastatic diagnosis is less than 1 year. Currently, there are known variants in germline DNA that associate with bronchial and pancreatic NENs, but not intestinal. We conducted an exome-wide association stud...

Background: Peptide-receptor-radionuclide-therapy (PRRT) improves progression free survival in metastatic neuroendocrine neoplasia (NEN). To be suitable for PRRT, somatostatin receptor-2 (SSTR2) must be present on tumour site as determined by positive uptake on [68Ga]Ga-DOTA-peptide-PET/CT. LANTana is an ongoing study evaluating whether treatment with the demethylating agent, ASTX727, results in re-expression of SSTR2, as determined by [68Ga]Ga-DOTA-peptide-PE...

Introduction: Surgery is the only known curative therapy for lung/bronchial neuroendocrine tumours (NET). Factors that affect survival after surgery for lung NET are not clear, and hence follow up protocols are not evidence-based.Methods: We collected data on 318 prospective patients that were operated on at a single centre between 2012 and 2020 (Guys and St Thomas’s regional thoracic surgery unit). The aim was to g...